Scientific Online Resource System

Scripta Scientifica Pharmaceutica

Market analysis of medicinal products for treatment of benign prostatic hyperplasia (BPH)

Steliana Yordanova, Galina Petrova, Jivko Kolev, Todorka Kostadinova


The aim of this article is to analyse the market of prescription medications for benign prostatic hyperplasia (BPH). The research is based mainly on IMS Health data on prescription medicines for BPH. Factors influencing the market of BPH-related medicines are prices, changes in the attitudes of doctors and the process of reimbursement. The market of products for treatment of BPH in Bulgaria has registered a steady growth for the past two years. Almost all participants in the market show development in number of sold packages/boxes.


analysis; market; treatment; products; benign prostatic hyperplasia

Full Text


Gacci M, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 2012 May; 61(5):994-1003.

Leveillee R. Patel V. Prostate hyperplasia, benign. 2010.

Wilt N`Dow J. Benign prostate hyperplasia Part 1 - Diagnosis. BMJ. 2008;336: 146-150.




Article Tools
Email this article (Login required)
About The Authors

Steliana Yordanova
Medical University of Varna

Galina Petrova
Medical University of Varna

Medical university of Varna, Faculty of public health, Department of economics and healthcare management, Assistant-in-chief

Jivko Kolev
Medical University of Varna

Medical university of Varna, Faculty of pharmacy department of pharmaceutical sciences and pharmaceutical management assistant

Todorka Kostadinova
Medical University of Varna

Medical University of Varna, Vice rector for international cooperation, accreditation and quality Faculty of public health professor in the department of economics and healthcare management

Font Size